Infliximab shows superior drug survival among biologics for hidradenitis suppurativa: A cohort study.

Competing Interests: Conflicts of interest Dr Hamzavi is a consultant for AbbVie, Pfizer, Incyte, UCB, Boehringer Ingelheim, Sonoma, Union Therapeutics, Novartis, Jansen, Avita, and Galderma; investigator for Lenicura, Pfizer, Incyte, Avita, and L'Oréal/La Roche-Posay; and past president of the HS Foundation and Global Vitiligo Foundation. Dr Huggins has been an investigator for Arcutis, Avita, Clinuvel, Incyte, Pfizer, Mitsubishi, and The Immune Tolerance Network. He is also the Treasurer of the Global Vitiligo Foundation (GVF) and the chair of the GVF community committee and served on advisory boards for Incyte and Avita. Drs Young, Adrianto, Zhou, and Mi and authors Lu and Dai have no conflicts of interest to declare.